Study to Assess the Efficacy and Safety of Omalizumab Treatment on ICS Reduction for Severe IgE-mediated Asthma
Clinical trial NCT01912872 · TERMINATED
Trial details
- NCT number
- NCT01912872
- Sponsor
- Novartis Pharmaceuticals
- Status
- TERMINATED
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2013-11-11
- Primary completion
- 2015-08-06
- Enrollment
- 112
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.